D.E. Shaw & Co
STOK icon

D.E. Shaw & Co’s Stoke Therapeutics STOK Stock Holding History

D.E. Shaw & Co’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.89M Buy
57,847
+7,875
+16% +$253K ﹤0.01% 3251
2026
Q1 		$1.63M Buy
49,972
+71
+0.1% +$2.33K ﹤0.01% 3077
2025
Q4 		$1.58M Sell
49,901
-2,712
-5% -$81.5K ﹤0.01% 3225
2025
Q3 		$1.24M Buy
52,613
+21,917
+71% +$376K ﹤0.01% 3325
2025
Q2 		$348K Buy
+30,696
New +$291K ﹤0.01% 3799
2025
Q1 		– Sell
-28,043
Closed -$309K – 4727
2024
Q4 		$309K Sell
28,043
-143,203
-84% -$1.76M ﹤0.01% 3871
2024
Q3 		$2.1M Buy
171,246
+34,236
+25% +$485K ﹤0.01% 2673
2024
Q2 		$1.85M Sell
137,010
-56,750
-29% -$766K ﹤0.01% 2719
2024
Q1 		$2.62M Buy
193,760
+51,049
+36% +$309K ﹤0.01% 2419
2023
Q4 		$751K Sell
142,711
-62,455
-30% -$267K ﹤0.01% 3318
2023
Q3 		$808K Buy
205,166
+88,701
+76% +$583K ﹤0.01% 3181
2023
Q2 		$1.24M Buy
116,465
+50,496
+77% +$537K ﹤0.01% 2951
2023
Q1 		$550K Sell
65,969
-2,866
-4% -$25.9K ﹤0.01% 3513
2022
Q4 		$635K Buy
68,835
+42,700
+163% +$444K ﹤0.01% 3723
2022
Q3 		$336K Buy
+26,135
New +$416K ﹤0.01% 4250
2022
Q1 		– Sell
-10,065
Closed -$241K – 5920
2021
Q4 		$241K Buy
+10,065
New +$240K ﹤0.01% 4789
2021
Q3 		– Sell
-7,143
Closed -$240K – 5219
2021
Q2 		$240K Sell
7,143
-4,714
-40% -$167K ﹤0.01% 4384
2021
Q1 		$461K Buy
+11,857
New +$675K ﹤0.01% 3542

Other funds holding STOK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

D.E. Shaw & Co's STOK Position: Q2 2026 in Review

D.E. Shaw & Co increased its Stoke Therapeutics (STOK) stake by 16% in Q2 2026, buying an estimated $253K and bringing the position to 57,847 shares worth $1.89M. The position accounts for ﹤0.01% of the portfolio, ranked #3251.

D.E. Shaw & Co first reported a position in STOK in Q1 2021 and has held it in 18 quarters since. The position peaked at $2.62M in Q1 2024. 197 funds tracked by Wall St. Rank hold STOK as of Q2 2026.

  • D.E. Shaw & Co held 57,847 shares of Stoke Therapeutics worth $1.89M as of Q2 2026.
  • D.E. Shaw & Co bought 7,875 Stoke Therapeutics shares in Q2 2026, an estimated $253K.
  • Stoke Therapeutics made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q2 2026, its #3251 holding.
  • D.E. Shaw & Co first reported a position in Stoke Therapeutics in Q1 2021 and has held it in 18 quarters since.
  • D.E. Shaw & Co's Stoke Therapeutics position peaked at $2.62M in Q1 2024.
  • 197 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.